Parkinson's costs Europe €23bn annually, with informal care burden underscored

Parkinson's disease is costing Europe €22.8 billion every year. That figure, drawn from a study commissioned by the European Academy of Neurology, represents the full weight of the condition across 47 European countries as of 2019—medical bills, lost wages, and the unpaid labor of family members who step in to care for someone as the disease progresses. Adjusted for inflation in the years since, researchers estimate the true current burden has climbed to €28.8 billion annually, a jump of €6 billion in six years.

The arithmetic breaks down into three distinct categories. Direct medical and non-medical costs—doctor visits, medications, home modifications—total €17.3 billion yearly. Then there is the work that nobody pays for. Family members, friends, and other unpaid caregivers provide assistance valued at €4.4 billion a year, nearly one-fifth of the entire burden. A further €1 billion evaporates through lost workplace productivity as people leave jobs or reduce hours to become caregivers themselves. For an individual living with Parkinson's, the mean annual cost reaches €14,278, though the median sits lower at €8,393, a gap that reflects how unevenly the disease and its expenses distribute across the continent.

Parkinson's is now the second most common neurodegenerative disorder worldwide and the fastest-growing. The economic pressure it creates poses what researchers describe as significant challenges for healthcare systems already stretched thin. Yet the study's authors encountered a fundamental problem in trying to map the full European picture: data simply does not exist in many places. The research relied heavily on information from wealthy nations. Lower-middle-income countries contributed little to the analysis, not because Parkinson's spares them, but because their healthcare systems do not systematically track or publish cost data. This transparency gap means the €22.8 billion figure, while substantial, likely understates the true burden.

Five countries account for roughly three-quarters of all the cost data researchers could gather. Germany leads at €5.7 billion annually, followed by France at €5.3 billion, Italy at €2.6 billion, Spain at €1.9 billion, and the United Kingdom at €1.6 billion. Richard Dodel, a professor of geriatrics and neurology at the University Duisburg-Essen, cautioned against reading these numbers as proof that Parkinson's is simply more expensive in wealthier nations. The concentration reflects multiple factors working together: larger populations, higher rates of Parkinson's in aging societies, the higher cost of healthcare in prosperous countries, and crucially, the simple fact that these nations maintain better records. "The concentration of costs in these five countries is likely due to a combination of their large populations, higher age-related prevalence of Parkinson's disease, higher healthcare costs in wealthier countries, and the greater availability of data, rather than any single factor," Dodel explained.

Amelia Hursey, Parkinson's Europe's Strategic Director and a co-author of the study, framed the research as more than an accounting exercise. Numbers like these, she argued, move policymakers. They make visible what is otherwise easy to ignore—the cascading costs of a disease that forces people out of work, that demands constant attention from family members who receive no salary, that requires adaptations to homes and vehicles and daily routines. "This work is so important for raising awareness among decision and policy makers," Hursey said. "It helps make them aware of how systems need to change and evolve to accommodate the increasing number of people diagnosed with Parkinson's in Europe every year."

The study underscores a critical gap: Europe has no unified system for tracking healthcare costs and outcomes across borders. Each country maintains its own records in its own way, if it maintains them at all. Researchers call for standardized methods of measurement, a shared infrastructure that would allow policymakers across the continent to see the true scope of Parkinson's and respond accordingly. Parkinson's Europe plans to use these findings as it engages with policymakers at forums like the European Health Forum, scheduled for late September, where conversations about brain health and environmental factors like pesticide exposure will take place. The data, in other words, is a tool—one that advocates hope will finally force the systems that serve people with Parkinson's to evolve.